[Acute low back pain induced by calcifying nucleopathy].

Rev Med Interne

Service de Médecine Physique et de Réadaptation, Hôpital Foch, 40, rue Worth, 92151 Suresnes cedex, France.

Published: July 2006

Introduction: The nucleopathy calcifying of the inter vertebral disk is mostly asymptomatic.

Case Record: We report a cave miming a spondylodiscit.

Discussion: Although idiopatic in most case, it is necessary to look for a calcifying metabolic disease. The treatment base on the immobilization of the spine and non steroidal anti inflammatory medications.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.revmed.2006.01.003DOI Listing

Publication Analysis

Top Keywords

[acute low
4
low pain
4
pain induced
4
induced calcifying
4
calcifying nucleopathy]
4
nucleopathy] introduction
4
introduction nucleopathy
4
nucleopathy calcifying
4
calcifying inter
4
inter vertebral
4

Similar Publications

Venetoclax plus azacitidine represents a key advance for older, unfit patients with acute myeloid leukemia (AML). The chemotherapy and venetoclax in elderly AML trial (CAVEAT) was first to combine venetoclax with intensive chemotherapy in newly diagnosed patients ≥65 years. In this final analysis, 85 patients (median age 71 years) were followed for a median of 41.

View Article and Find Full Text PDF

Study of Children Aged Under 2 Years Admitted With RSV at Four Australian Hospitals [2021-2022].

J Paediatr Child Health

January 2025

WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Doherty Institute, Melbourne, Victoria, Australia.

Aims: Primary aim was to review severe acute respiratory infections (SARI) hospitalisations caused by respiratory syncytial virus (RSV) in children aged < 2 years in paediatric hospitals in Australia. Secondary aims included RSV subtyping, assessing RSV seasonality and contributing to the World Health Organisation's RSV surveillance programme.

Methods: We prospectively reviewed the medical records of children (< 2 years of age) with a confirmed SARI who were admitted to one of four major Australian paediatric hospitals and had a respiratory sample analysed by Polymerase Chain Reaction (PCR).

View Article and Find Full Text PDF

Anti-CD19 chimeric antigen receptor T cells (CAR) are a well-established treatment option for children and young adults suffering from relapsed/refractory B-lineage acute lymphoblastic leukemia. Bridging therapy is used to control disease prior to start of lymphodepletion before CAR infusion and thereby improve efficacy of CAR therapy. However, the effect of different bridging strategies on outcome, side effects and response to CAR therapy is still poorly understood.

View Article and Find Full Text PDF

Screening for transcriptomic associations with Swine Inflammation and Necrosis Syndrome.

BMC Vet Res

January 2025

Department of Veterinary Clinical Sciences, Clinic for Swine, Justus-Liebig-University, Frankfurter Strasse 112, D-35392, Giessen, Germany.

Background: The recently identified swine inflammation and necrosis syndrome (SINS) affects tail, ears, teats, coronary bands, claws and heels of affected individuals. The primarily endogenous syndrome is based on vasculitis, thrombosis, and intimal proliferation, involving defence cells, interleukins, chemokines, and acute phase proteins and accompanied by alterations in clinical chemistry, metabolome, and liver transcriptome. The complexity of metabolic alterations and the influence of the boar led to hypothesize a polygenic architecture of SINS.

View Article and Find Full Text PDF

Background: Hypomethylating agents (HMA), such as azacytidine (AZA) and decitabine (DAC), are epigenetic therapies used to treat some patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome. HMAs act in a replication-dependent manner to remove DNA methylation from the genome. However, AML cells targeted by HMA therapy are often quiescent within the bone marrow, where oxygen levels are low.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!